Biotech Values

[DewDiligence]

True for IFN-containing treatments, but may not be true for DAA only.

Agreed. The possibility that SVR24 might not be the universally accepted efficacy metric for all-oral regimens complicates things immensely from an investment standpoint. Assuming that ABT’s result in #msg-74608528 was not a fluke, I predict that it will take a while before all this gets sorted out.